Document Detail

Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5.
MedLine Citation:
PMID:  10821648     Owner:  NLM     Status:  MEDLINE    
HER2/neu oncogene encodes a 185 kDa trans-membrane protein which is overexpressed in 20-30% of breast and ovarian cancers and portends a poor prognosis. We have studied the targeting and therapy of this oncoprotein with 4D5, a murine monoclonal antibody which recognizes a distinct epitope on the extracelluar domain of HER2/neu. We conjugated the antibody with an active ester of the macrocyclic chelating agent DOTA, radiolabeled the conjugate with either (111)In or (90)Y, and studied the antibody distribution and therapy, respectively, in athymic mice bearing xenografts of MCF7/HER2/neu, a human breast cancer cell line transfected with the HER2/neu oncogene. For the biodistribution of (111)In-labeled DOTA-4D5, a high specificity of tumor localization (30% ID/g) was seen with a tumor-to-blood ratio of greater than 2 at 48 h postinjection. Compared to a previously published study with (125)I-labeled 4D5 in beige nude mice bearing NIH3T3/HER2/neu xenografts [De Santes et al. (1992) Cancer Res. 52, 1916-1923], (111)In-labeled 4D5 antibody gave superior antibody uptake in tumor (30% ID/g vs 17% ID/g at 48h). In the therapy study, treatment of the nude mice bearing MCF7/HER2/neu xenografts with 100 microCi (3 microg) of (90)Y-labeled DOTA-4D5 caused a 3-fold reduction of tumor growth compared to untreated controls (injected with human serum albumin) in 40 days. Treatment of animals with 100 microCi of nonspecific antibody (90)Y-labeled DOTA-Leu16 (3 microg) had no tumor growth inhibition. Treatment with unlabeled DOTA-4D5 (3 microg) had a slight effect on tumor growth compared to untreated controls. When analyzed at the level of single animals, no effect was seen in seven of nine animals; however, in two of the animals, tumor growth inhibition was observed. Although a cold antibody therapeutic effect was unexpected at this dose level (3 microg), it may be possible that in some animals that 3 microg of antibody of (90)Y-labeled DOTA-4D5 augmented tumor growth reduction. To further explore the effects of cold antibody treatment alone, animals were treated with 100 or 400 microg of unlabeled 4D5 administered in two doses. These animals showed a 1.7-1.8-fold reduction in tumor growth over 28 days, a result less than that obtained with RIT only.
S W Tsai; Y Sun; L E Williams; A A Raubitschek; A M Wu; J E Shively
Related Documents :
6223818 - Studies on 18f-labeled pyrimidines. tumor uptakes of 18f-5-fluorouracil, 18f-5-fluorour...
11337558 - Biodistribution and dosimetry of pretargeted monoclonal antibody 2d12.5 and y-janus-dot...
12791828 - Increased mibg uptake after transfer of the human norepinephrine transporter gene in ra...
17583928 - Design and synthesis of mono- and multimeric targeted radiopharmaceuticals based on nov...
16911458 - Decreased expressions of hepsin in human hepatocellular carcinomas.
10842198 - Monoclonal antibody 57b stains tumor tissues that express gene mage-a4.
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, Non-P.H.S.    
Journal Detail:
Title:  Bioconjugate chemistry     Volume:  11     ISSN:  1043-1802     ISO Abbreviation:  Bioconjug. Chem.     Publication Date:    2000 May-Jun
Date Detail:
Created Date:  2000-07-31     Completed Date:  2000-07-31     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  9010319     Medline TA:  Bioconjug Chem     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  327-34     Citation Subset:  IM    
Division of Immunology, Beckman Research Institute of the City of Hope, Duarte, California 91010, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / analysis,  therapeutic use*
Breast Neoplasms
Chelating Agents*
Indium Radioisotopes
Mammary Neoplasms, Experimental / pathology,  radiotherapy*
Mice, Nude
Neoplasm Transplantation
Organometallic Compounds / therapeutic use*
Receptor, erbB-2 / immunology*
Tissue Distribution
Transplantation, Heterologous
Tumor Cells, Cultured
Yttrium Radioisotopes
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Chelating Agents; 0/DOTA-4D5; 0/Indium Radioisotopes; 0/Organometallic Compounds; 0/Yttrium Radioisotopes; EC, erbB-2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Synthesis of cholesteryl polyamine carbamates: pK(a) studies and condensation of calf thymus DNA.
Next Document:  Molecular characterization of a tetramolecular complex between dsDNA and a DNA-binding leucine zippe...